The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
Open accessAbstract
Objective Persons with schizophrenia die earlier than the general population, in large part due to cardiovascular disease. The study objective was to examine effects of different antipsychotic treatments on estimates of 10-year coronary heart disease (CHD) risk calculated by the Framingham Heart Study formula.Method Change in 10-year risk for CHD was compared between treatment groups in 1125 patients followed for 18 months or until treatment discontinuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial.Results The covariate-adjusted mean change in 10-year CHD risk differed significantly between treatments. Olanzapine was associated with a 0.5% (SE 0.3) increase and quetiapine, a 0.3% (SE 0.3) increase; whereas risk decreased in patients treated with perphenazine, -0.5% (SE 0.3), risperidone, -0.6% (SE 0.3), and ziprasidone -0.6% (SE 0.4). The difference in 10-year CHD risk between olanzapine and risperidone was statistically significant (p=0.004). Differences in estimated 10-year CHD risk between drugs were most marked in the tertile of subjects with a baseline CHD risk of at least 10%. Among individual CHD risk factors used in the Framingham formula, only total and HDL cholesterol levels differed between treatments.Conclusions These results indicate that the impact on 10-year CHD risk differs significantly between antipsychotic agents, with olanzapine producing the largest elevation in CHD risk of the agents studied in CATIE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Daumit et al. (2008) analyzed changes in 10-year coronary heart disease risk estimates during the 18-month CATIE trial by antipsychotic treatment, and they found that treatment with olanzapine and quetiapine was associated with a higher long-term risk of cardiovascular disease than was treatment with perphenazin, risperidone, and ziprasidone.”
From Excess early mortality in schizophrenia. (2014) · cites this paper as Daumit et al. 2008
In the citing paper
“Several factors contribute to the early and frequent development of cardiovascular disease in this population, including genetic vulnerability 5 , metabolic adverse effects of antipsychotics 6,7 , insufficient treatment of somatic comorbidity 8 , and unhealthy lifestyle 9 .”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citationAntipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
D'Agostino, R. B., Grundy, S., Sullivan, L. M., Wilson, P., & for the CHD Risk Prediction Group (2001) · JAMA · doi:10.1001/jama.286.2.180 · Cited by 2,108
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
(1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410020010002 · Cited by 1,974
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
(2006) · Europe PMC (PubMed Central) · Cited by 1,299
Mcevoy, J., Meyer, J., Goff, D., Nasrallah, H., Davis, S., Sullivan, L., Meltzer, H., Hsiao, J. K., Stroup, T., & Lieberman, J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,220
Self-citation
Cited by
Sorted by citations
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
Excess early mortality in schizophrenia.
Laursen, T. M., Nordentoft, M., & Mortensen, P. B. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153657 · Cited by 913
Metadata
- Authors
- Daumit, G. L., Goff, D. C., Meyer, J. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P., Rosenheck, R., Davis, S. M., Hsiao, J. K., Stroup, T. S., & Lieberman, J. A.
- Affiliations
- Johns Hopkins University (US)
- Harvard University (US)
- University of California San Diego (US)
- Bank of America (US)
- University of Cincinnati (US)
- Duke University (US)
- Yale University (US)
- National Institutes of Health (US)
- University of North Carolina at Chapel Hill (US)
- Columbia University (US)
- Corresponding author
- Daumit, Gail L.
- ORCID
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 105
- Issue
- 1-3
- Pages
- 175-187
- ISSN
- 0920-9964 (ISSN-L)
- PMC
- PMC2614656
- OpenAlex
- W2107325590
- Cited by
- 223
- References
- 44
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 8 · 2023: 2 · 2022: 6 · 2021: 9 · 2020: 6 · 2019: 11 · 2018: 11 · 2017: 13 · 2016: 10 · 2015: 20 · 2014: 16 · 2013: 24 · 2012: 20
- FWCI
- 14.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Schizophrenia Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (1MH900001)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- antipsychotic drugs, coronary heart disease risk
- MeSH terms
- Adult, Coronary Disease, Female, Follow-Up Studies, Humans, Hypertension, Longitudinal Studies, Male, Obesity, Patient Dropouts, Risk Factors, Schizophrenia, Schizophrenic Psychology, Smoking, Antipsychotic Agents, Weight Gain, Comorbidity, Treatment Outcome, Outcome Assessment, Health Care, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
